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Background
Family history-based risk assessment (FHRA) is a vali-
dated genetic tool for identifying those at moderate and
high risks of disease. The latter usually result from gene
mutations conferring high risks of disease. Genome-
wide association studies (GWAS) have resulted in single
nucleotide polymorphisms (SNP) statistically associated
with low- to moderate-level risks of diseases or traits.
With increased access and decreasing price-point for
SNP profile-based risk assessment for common diseases,
such as colon cancer, health-professionals and consu-
mers are questioning how this type of genetic risk
assessment compares to the standard of FHRA. To date,
there has been limited study of concordance for these
two methods of disease-risk assessment.
Materials and methods
We compared FHRA with Navigenics personal genomic
screening (PGS) for colon cancer in 44 subjects (22 males,
22 females) ascertained from our genetics clinics at the
Genomic Medicine Institute at Cleveland Clinic. Each sub-
ject was categorized as low/general population, moderate,
or high risk based on FHRA and PGS results. Concor-
dance of FHRA and PGS categorizations was assessed
with the kappa (K) statistic. We also assessed each
subject’s hereditary risk based on clinical criteria and/or
validated gene test results.
Results
Both FHRA and PGS placed 44% of participants into
the same risk categories. Overall, however, the concor-
dance between FHRA and PGS risk assessments was
low (K=-0.05). There were 17 subjects with a moderate
colorectal cancer risk on PGS whereas FHRA classified
12 as general population risk and 3 at high risk. Simi-
larly, FHRA classed 7 subjects as high risk for colorectal
cancer whereas none were noted as high risk by PGS.
FHRA classified 9 subjects with hereditary risk for col-
orectal cancer, of whom 5 met syndromic clinical cri-
teria while the remaining 4 had family histories meeting
hereditary colorectal cancer criteria, but none of these 9
were classified by PGS as high risk (p=0.0001).
Conclusions
FHRA and PGS may be complementary tools for colon
cancer risk assessment. However, evaluation of family
history remains the gold standard, and this should be
used to clinically evaluate an individual’s risk of develop-
ing colon cancer until further research demonstrates
PGS can be integrated with family-based assessment to
increase sensitivity.
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